Biogen BIIB Alzheimer's Collaboration — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's alzheimer's collaboration — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's alzheimer's collaboration — total revenue?
- Biogen (BIIB) reported alzheimer's collaboration — total revenue of $59.5M in Q1 2026.
- How has Biogen's alzheimer's collaboration — total revenue changed year-over-year?
- Biogen's alzheimer's collaboration — total revenue increased by 80.3% year-over-year, from $33M to $59.5M.
- What does alzheimer's collaboration — total revenue mean?
- This metric represents the total recognized revenue generated from products, licensing, or commercial partnerships specifically focused on Alzheimer's disease therapeutics. It captures the financial performance of the company's strategic initiatives in neurodegenerative disease treatment, often involving shared profit or royalty structures with external collaborators. This revenue stream is critical for assessing the commercial traction and market adoption of the company's high-stakes pipeline assets in the neurology space.